Immunology Drugs Market Key Players Analysis - Eli Lilly, AbbVie Inc, F.Hoffmann-La roche Ltd, Amgen Inc, Pfizer.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Global Immunology Drugs Market By Drug Class (Monoclonal antibodies, Fusion Proteins, Immunosuppressants, Polyclonal antibodies, and Other Drug classes), Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), Disease Indications (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, and Other disease Indication))- Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

The Immunology Drugs Market Size is estimated to grow at a CAGR of 10% during the forecast period for 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1328

Immunology drugs are pharmaceutical agents that modify the immune response by either stimulating or suppressing the immune system. These drugs are utilized to treat or prevent various autoimmune and immunological disorders and to combat infections. The increasing awareness of immunological diseases in both emerging and developed markets, along with the rising prevalence of these disorders due to environmental factors, are key drivers fueling the expansion of the global immunology drugs market.

A significant patient population is affected by autoimmune diseases, driven by environmental factors such as infections, stress, dietary habits, gut microbiome imbalances, and exposure to hazardous substances. The high global demand for immunology drugs has prompted market participants to invest heavily in research and development. Moreover, growing awareness of autoimmune diseases and a promising pipeline of new drug candidates in both developed and emerging markets are expected to drive market growth during the forecast period. Clinical trial data suggest that immunology drugs can deliver long-lasting therapeutic effects, even after the initial reduction of tumor size, by priming the immune system to target cancer cells.

Despite the increasing prevalence of immunological diseases, several factors are expected to constrain market growth over the forecast period. High production costs and adverse side effects present significant challenges. The expense of biologics remains high due to the complex manufacturing processes and substantial investments required for research and development, including navigating the FDA approval process and clinical trials.

North America is expected to dominate the global immunology drugs market. The United States holds a leading position due to its advanced healthcare infrastructure, high prevalence of chronic diseases, and relatively higher diagnosis and treatment rates. Increasing patient demand for treatment options and heightened public awareness are expected to further drive market growth throughout the forecast period.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Prominent players in the immunology drugs market are Eli Lilly Company, AbbVie Inc, F.Hoffmann-La roche Ltd, Amgen Inc, Pfizer, Novartis, Astellas, Alector, ImmuNext, Merck sharp & Dohme Corp., UCB SA, and other prominent players.

Key Developments In The Market:
• In Jun 2022, FDA authorised RIABNITM (rituximab-arrx) for use in individuals with moderately to severely active rheumatoid arthritis (RA) who have not responded effectively to one or more TNF antagonist treatments. Amgen has eleven biosimilars under development, including cancer and chronic inflammatory disease therapies.
• In May 2022, AbbVie and Cugene announced a worldwide licence option agreement for CUG252, a possible best-in-class Treg-selective IL-2 mutein, and additional new IL-2 muteins for the treatment of autoimmune and inflammatory disorders. Cugene will receive an upfront payment of $48.5 million, development and regulatory milestone payments, and a licence option exercise payment if AbbVie exercises the option.
• In Sept 2021, Lycia Therapeutics and Eli Lilly and Company announced a multiyear research collaboration and licence agreement to explore, develop, and commercialise new targeted pharmaceutical candidates. The companies will utilise Lycia Therapeutics' LYTAC (lysosomal targeting chimaera) platform to identify and develop drug candidates for up to five targets in Eli Lilly & Company's therapeutic areas, such as immunology and pain.
• In July 2020, The Janssen Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) had approved an expanded indication for STELARA (ustekinumab) as a treatment for young patients (ages 6 to 11) who struggle with the skin lesions or plaques connected to moderate to severe plaque psoriasis (PsO). STELARA targets interleukin (IL)-12 and IL-23, two cytokines thought to be crucial in regulating the excessive inflammatory response in various autoimmune diseases, including PsO.
• In May 2020, AbbVie announced that it had completed its purchase of Allergan plc after receiving regulatory approval from all government bodies needed by the deal agreement. The deal considerably broadens and diversifies AbbVie's income stream and strengthens the company's already-established leadership positions in Immunology Drugs with Humira, hematologic oncology with Imbruvica, and Rinvoq.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1328

Global Immunology Drugs Market, by by Drug Class, 2022-2030 (Value US$ Bn)
• Monoclonal antibody
• Fusion Proteins
• Immunosuppressant
• Polyclonal antibody
• Other Drug Class
Global Immunology Drugs Market, by Distribution Channel, 2022-2030 (Value US$ Bn)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channel
Global Immunology Drugs Market, by Disease Indications, 2022-2030 (Value US$ Bn)
Rheumatoid Arthritis
• Psoriatic Arthritis
• Plaque Psoriasis
• Ankylosing Spondylitis
• Inflammatory Bowel disease
• Other disease Indication
Global Immunology Drugs Market, by Region, 2022-2030 (Value US$ Bn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Immunology Drugs Market, by Country, 2022-2030 (Value US$ Bn)
• U.S.
• Canada
Europe Immunology Drugs Market, by Country, 2022-2030 (Value US$ Bn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Immunology Drugs Market, by Country, 2022-2030 (Value US$ Bn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Immunology Drugs Market, by Country, 2022-2030 (Value US$ Bn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Immunology Drugs Market, by Country, 2022-2030 (Value US$ Bn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Why should buy this report:
• To receive a comprehensive analysis of the prospects for the pipeline products in the global immunology drugs market
• To receive an industry overview and future trends of the immunology drugs market
• To analyze immunology drugs market drivers and challenges
• To get information on the immunology drugs market size (Value US$ Bn) forecast to 2030
• To get the information on investments, mergers & acquisitions in the immunology drugs market industry

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.